Kite Pharma Inc (NASDAQ:KITE) shares are on the run, after the drug maker announced the much-awaited top line results from its Phase 2 ZUMA-1 …
Kite Pharma Inc (NASDAQ: KITE) provided a corporate update and reported fourth quarter and full-year 2016 financial results for the period that ended December …
Kite Pharma Inc (NASDAQ:KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo Co., Ltd.
The biotech-verse was buzzing this week after Kite Pharma Inc (NASDAQ:KITE) submitted an IND application for its pipeline cancer drug that sent shares rising. …
Kite Pharma Inc (NASDAQ: KITE) announced that Ian T. Clark, former Chief Executive Officer, Head of Commercial Operations and member of the Board of …
Kite Pharma Inc (NASDAQ: KITE) announced that it has submitted an Investigational New Drug (IND) application with the U.S.
Kite Pharma Inc (NASDAQ: KITE) announced several updates to its broad intellectual property portfolio relating to the use of chimeric antigen receptors (CARs) …
Kite Pharma Inc (NASDAQ:KITE) and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures …
Kite Pharma Inc (NASDAQ:KITE) announced that characterizations of T cell receptor candidates which it has licensed under the Cooperative Research and Development Agreement …
Kite Pharma Inc (NASDAQ: KITE) presented results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) …
